Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 9,12 € (+334,29 %). Medianen er 9,12 € (+334,29 %).
| Køb |
4 |
| Behold |
14 |
| Sælg |
2 |
Diskussioner i communityet
- Wie eine Fusion eintragen?
Hallo, meine Terraform Power Aktien wurden durch eine Fusion mit Brookfield Renewable umgetauscht. Wie trage ich das in T1 richtig ein? Verkauf für 0€ und die neue Aktie für 0€ einbuchen? Aber dann…
J Johann I i Schnack
0 10
Nyheder Til nyhedsfeedet
Tilray Brands (ex Aphria) raises quarterly revenue to USD 257.2 million (+22.7%)
Tilray Brands (ex Aphria) reported for the quarter ended August 31, 2026 a revenue increase of 22.74% to USD 257.2 million, compared with USD 209.5 million a year earlier. The earnings figure was released on October 8, 2026. » Mere på finanzen.net
Tilray invests £50m in BrewDog to improve beers, pubs and working conditions
Tilray, which bought BrewDog in March for £33m after the brewer entered administration, is investing more than £50m to improve beer quality, reopen and upgrade selected bars, raise pay and improve working conditions. The company is upgrading the Aberdeenshire brewery, launching new beers, introducing US craft lines into BrewDog venues and considering further UK craft acquisitions. Administrators said creditors will not be repaid in full and crowdfunding shares were rendered worthless, though some investor benefits and supplier continuity have been maintained. » Mere på theguardian.com
Tilray positioned to benefit if Trump advances marijuana rescheduling
A federal appeals court refused to pause the Biden administration's move to consider broader rescheduling of marijuana, keeping alive a proposal to reclassify cannabis to Schedule III. Schedule III would not legalize recreational use or interstate commerce but could ease research and expand medical opportunities that would help Tilray's international medical cannabis business. Tilray reported record fiscal 2026 revenue, sharply improved cash flow and near-elimination of net debt, and management sees U.S. rescheduling as a future growth opportunity. Legal challenges and timing remain uncertain, so potential investors should view rescheduling as upside rather than a guaranteed catalyst. » Mere på finance.yahoo.com
Tilray Brands posts record fiscal 2026 revenue but shares fail to rally
Tilray Brands reported record fiscal 2026 revenue of about $915 million and an 11% rise in adjusted EBITDA to $61.1 million, with adjusted net income nearly doubling to $12.2 million. The results nonetheless missed sell-side forecasts and the company recorded a GAAP net loss of $49.6 million. Management guided to modest adjusted EBITDA growth for fiscal 2027 and has reduced debt largely through dilutive debt-for-equity swaps, while cannabis now represents only 29% of sales, leaving investors hesitant to drive the stock higher. » Mere på finance.yahoo.com
Tilray increases global cultivation capacity for medical cannabis to around 275 tonnes
Tilray has expanded its annual cultivation capacity from 210 to about 275 tonnes, mainly through production increases in Quebec and at the EU‑GMP‑certified plant in Portugal. Quebec now supplies large volumes to sites in Portugal and Australia, is aiming for EU‑GMP certification within 12 months and has built up inventories for international markets. In Germany the Aphria RX facility is running at full capacity and the new ARX brand has been launched, strengthening Tilray’s supply infrastructure for Europe, the UK and other regulated markets. » Mere på finanzen.net
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | august 2026 | YoY |
|---|---|---|
| Omsætning | 221,35 mio. | 23,51 % |
| Bruttofortjeneste | 66,72 mio. | 35,72 % |
| Nettoresultat | -37,13 mio. | 13.382,06 % |
| EBITDA | -11,35 mio. | 161,77 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 229,37 mio. € |
Antal aktier | 111,83 mio. |
Højeste/laveste i 52 uger | 14,31 € - 2,03 € |
| Udbytte | Nej |
Beta | 2,05 |
P/E (PE Ratio) | -1,61 |
PEG (PEG Ratio) | -0,02 |
K/I (PB Ratio) | 0,18 |
P/S (PS Ratio) | 0,26 |
Virksomhedsprofil
Tilray Brands Inc. beskæftiger sig med forskning, dyrkning, produktion, markedsføring og distribution af medicinske cannabisprodukter. Virksomheden er organiseret i fem segmenter: Cannabisforretning, Distributionsforretning, Forretning med alkoholiske drikkevarer, Wellnessforretning og Forretning under udvikling. Selskabet leverer medicinske og voksenrettede cannabisprodukter, farmaceutiske produkter og wellnessprodukter, alkoholiske drikkevarer samt hampbaserede fødevarer og andre wellnessprodukter. Produkterne sælges til detailhandlere, grossister, patienter, læger, apoteker, klinikker, hospitaler, offentlige myndigheder og forskere. Virksomheden driver Tilray Medical, en medicinsk platform, der tilbyder GMP-certificerede blomster, olier, vapes, spiselige produkter og topikale produkter. Selskabet har aktiviteter i Canada, USA, Europa, Australien, New Zealand, Latinamerika og internationalt. Virksomheden var tidligere kendt som Tilray, Inc. Tilray Brands Inc. blev stiftet i 2018 og har hovedkontor i New York, New York.
| Navn | Tilray |
| CEO | Irwin David Simon |
| Hjemsted | Leamington,
on USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 19.07.2018 |
| Medarbejdere | 3.595 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | TLRY |
Toronto Stock Exchange | TLRY.TO |
XETRA | 2HQ.DE |
Frankfurt | 2HQ.F |
Düsseldorf | 2HQ.DU |
Hamburg | 2HQ.HM |
SIX | 2HQ.SW |
München | 2HQ.MU |
Wien | TLRY.VI |